NestaCell (mesenchymal stem cells)
/ Cellavita Scientific Research
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
December 06, 2025
Progress and Perspectives in Allogeneic Cell-Based Pulp Regeneration.
(PubMed, Int Endod J)
- "Despite encouraging preliminary results, significant limitations remain in the establishment of standardised protocols and the development of reliable techniques for longitudinal cell tracking. In future research, optimised delivery systems, immune-evasive cell engineering and rigorous clinical trial designs should be optimised to advance REPs towards predictable, clinically viable therapies."
Journal • Inflammation • Transplantation
November 05, 2025
A phase I, open-label study of intravenous human dental pulp stem cells (NestaCell®) at two dose levels in patients with Huntington's disease.
(PubMed, Stem Cell Res Ther)
- P1 | "hDPSCs infusions were well tolerated and exhibited a favourable safety profile, even with prolonged exposure and follow-up. These findings support the continued clinical development and warrant further investigation in more extensive trials to assess therapeutic efficacy in Huntington's disease."
Journal • CNS Disorders • Critical care • Depression • Huntington's Disease • Lung Cancer • Movement Disorders • Oncology • Solid Tumor • CD4 • CD8
August 07, 2025
Phase II trial of intravenous human dental pulp stem cell therapy for Huntington's disease: a randomized, double-blind, placebo-controlled study.
(PubMed, Stem Cell Res Ther)
- P2 | "NestaCell® was well tolerated and showed statistically significant improvements in motor and functional outcomes in HD patients. While MRI trends suggest a potential neuroprotective effect, further investigation is warranted. These findings support the advancement to a Phase III trial to confirm efficacy and long-term safety in a larger cohort."
Clinical • Journal • P2 data • CNS Disorders • Huntington's Disease • Inflammation • Movement Disorders
October 24, 2023
STAR: Efficacy and Safety of NestaCell® in Huntington's Disease
(clinicaltrials.gov)
- P3 | N=120 | Not yet recruiting | Sponsor: Azidus Brasil
New P3 trial • Genetic Disorders • Huntington's Disease • Movement Disorders
September 08, 2022
Advanced cell therapy with low tissue factor loaded product NestaCell® does not confer thrombogenic risk for critically ill COVID-19 heparin-treated patients.
(PubMed, Biomed Pharmacother)
- "Since the COVID-19 pandemic started, mesenchymal stromal cells (MSC) appeared as a therapeutic option to reduce the over-activated inflammatory response and promote recovery of lung damage. Our COVID-19 clinical study measured and selected the therapeutic cells with low TF (less than 25% of TF+ hIDPSCs). Our data indicate that the concomitant administration of enoxaparin and low TF-loaded is safe even for critically ill COVID-19 patients."
Journal • Infectious Disease • Inflammation • Novel Coronavirus Disease
April 18, 2020
HOPE: NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia
(clinicaltrials.gov)
- P1; N=66; Not yet recruiting; Sponsor: Azidus Brasil; N=24 ➔ 66
Clinical • Enrollment change • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases
March 25, 2020
Newly added product
(clinicaltrials.gov)
- Preclinical, Novel Coronavirus Disease
Pipeline update
1 to 7
Of
7
Go to page
1